

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION

FDA

FDA ADVISORY No. 2019-384

15 OCT 2019

TO

ALL HEALTHCARE PROFESSIONALS AND THE GENERAL

PUBLIC

SUBJECT:

Public Health Warning Against the Purchase and Use of the

Following Unregistered Drug Products:

1. OTC QING HUO PIAN

2. MIAOYAO JIAOQIWANG SHADUKANG PENJI

3. JIANGXI MINJI XIAN ZHU LI

4. OTC FANGFENG TONGSHENG WAN

5. GUI ZHI FU LING WAN

6. OTC TAIJI® SANLIETONG COMPOUND PARACETAMOL TABLETS (II)

7. OTC FOLIC ACID TABLETS [as reflected in the Package Insert]

8. ROXITHROMYCIN TABLETS

9. OTC MILIAN CHUANBEI PIPA GAO

10. NANCHANG® [Label in Foreign Language]

11. OTC NONGSUOWAN MAIWEI DIHUANGWAN

12. PANTUO LAZUONA CHANGRONGPIAN

13. OTC SHENG MAI YIN (DANG SHEN FANG)

14. OINGLIN KELI [as reflected in the Package Insert]

15. RIBAVIRIN INJECTION

16. OTC [Label in Foreign Language]

17. PIDI® COLCHICINE TABLETS

18. OTC CNWM XIONGDAN ZHILING SHUAN

19. [Label in Foreign Language]

20. OTC CICLOPIROX OLAMINE CREAM [as reflected in the Package Insert]

21. OMEPRAZOLE ENTERIC CAPSULE

22. OTC TIAOJING ZHITONG JIAONANG [as reflected in the Package Insert]

23. NUO FU SHA XING JIAONANG

24. DA NING TANG LIAN QIAO BAI DU PIAN

25. OTC QINGYUAN CALCIUM GLUCONATE TABLETS

26. BAI NIAN SAN WEI


27. CHUZHI SHENGFA PIAN

28. OTC ZEYSUB® [Label in Foreign Language]

29. OTC OUAN LU WAN

30. TIANRANCAOBENPEIFANG YIGANERJING

31. OTC LORATADINE TABLETS









- 32. OTC SUL FUR OINTMENT [as reflected in the Primary Packaging]
- 33. OTC LACONCORDE NAPHAZOLINE HYDROCHLORIDE, CHLORPHENAMINE MALEATE AND VITAMIN B₁₂ EYE DROPS (CONTAINING SODIUM HYALURONATE)
- 34. OTC BUSHEN QIANGSHEN JIAONANG
- 35. OTC [Label in Foreign Language]
- 36. OTC [Label in Foreign Language]
- 37. [Label in Foreign Language]
- 38. RHINITIS SPRAY
- 39. WEI A NING HERBACEOUS EXTRACTION ANTIBACTERIAL
- 40. OTC SANJIN® PIAN
- 41. OTC [Label in Foreign Language]
- 42. [Label in Foreign Language]
- 43. OTC GLYCERINE ENEMA
- 44. ZJIACHMEI LANG DU JUN E JING

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:



Figure 1. Unregistered drug product



Figure 2. Unregistered drug product



Figure 3. Unregistered drug product



Figure 4. Unregistered drug product







Figure 7. Unregistered drug product



Figure 8. Unregistered drug product





Figure 10. Unregistered drug product



Figure 11. Unregistered drug product



Figure 12. Unregistered drug product



Figure 13. Unregistered drug product



Figure 14. Unregistered drug product



Figure 15. Unregistered drug product





Figure 16. Unregistered drug product



Page 10 of 24







OTC CNWM Xiongdan Zhiling Shuan

ZHONGTAIYAOYE

Shandong Zhongtai Pharmaceutical Co. Ltd.

Figure 18. Unregistered Drug Product



Figure 19. Unregistered Drug Product



Figure 20. Unregistered Drug Product

.





Figure 22. Unregistered Drug Product



Figure 23. Unregistered Drug Product



Figure 24. Unregistered Drug Product



Figure 25. Unregistered Drug Product





Figure 26. Unregistered Drug Product









OTC ZEYSUB® [Label in Foreign Language] ZHENGYUANSHENGBANG PHARMACEUTICALCO.,LTD

Figure 28. Unregistered Drug Product





OTC QUAN LU WAN
Figure 29. Unregistered Drug Product



Figure 30. Unregistered Drug Product



Figure 31. Unregistered Drug Product



Figure 32. Unregistered Drug Product



Figure 33. Unregistered Drug Product



Figure 34. Unregistered Drug Product



Figure 35. Unregistered Drug Product



Figure 36. Unregistered Drug Product



Figure 37. Unregistered Drug Product





Figure 38. Unregistered Drug Product



Figure 39. Unregistered Drug Product



Figure 40. Unregistered Drug Product



Figure 41. Unregistered Drug Product



Figure 42. Unregistered Drug Product





Figure 43. Unregistered Drug Product



Figure 44. Unregistered Drug Product

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration and testing process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee their quality and safety. The consumption of such violative products may pose potential danger or injury if administered.

Pursuant to Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.

In light of the above, the public is advised not to purchase the aforementioned violative products and to be vigilant against it. Always check if a drug product has been registered with the FDA before purchasing it by making use of the embedded *Search* feature of the FDA website accessible at **www.fda.gov.ph**. You may also look for the FDA Registration number on the product label.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via report@fda.gov.ph, or through the online reporting facility, eReport, at www.fda.gov.ph/ereport. You may also call the Center for Drug Regulation and Research at telephone number (02)809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: www.fda.gov.ph/adr-report-new and fill out all the required fields.

Dissemination of the information to all concerned is requested.

ROLANDO ENRIQUE D. DOMINGO, MD, DPBO

Undersecretary of Health Officer-in-Charge, Director General

20190809090206